LIXT (LIXT)
Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Market Cap
—
P/E (TTM)
—
EPS
—
Div Yield
—
52W Range
—
Beta
—
Company overview
Live quote temporarily unavailable — press releases and news are still shown below.
No company overview is available for LIXT yet.
Peers in Biotechnology
All in industry →VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%
Recent press releases
LIXT has not issued a press release in this window.
SEC filings
All filings →LIXT has not filed an SEC document in this window.
Insider trades
All insider trades →LIXT has no reported insider trades in the last 90 days.
Institutional holders
All holders →As of 2025-12-31 · prior 2025-09-30
SCOTIA CAPITAL INC.$1.0M
258,713 sh● NEW
93,380 sh+83.6%
UBS Group AG$2,971
756 sh-95.5%
TWO SIGMA INVESTMENTS, LP$59,634
15,174 sh● NEW
XTX Topco Ltd$57,162
14,545 sh● NEW
CITADEL ADVISORS LLC$55,385
14,093 sh● NEW
RENAISSANCE TECHNOLOGIES LLC$422,475
107,500 sh+47.0%
13,771 sh● NEW
People at LIXT
All people →Quarterly financials
Full financials →Revenue trend
03/25
—
NI -$709.6K
06/25
—
NI -$775.7K
09/25
—
NI -$2.0M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.33
Prior: $-0.29
Revenue sparkline